Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby A Eyre

Showing results (71-80 of 163) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|June 14, 2021
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)Toby A Eyre, Gavin Preston, Huseini Kagdi, et al.
Blood Advances|February 11, 2020
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemiaVictoria M Smith, Oliver Lomas, Donna Constantine, et al.
British Journal of Haematology|January 22, 2024
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology GuidelineChristopher P Fox, Sridhar Chaganti, Graham McIlroy, et al.
Leukemia & Lymphoma|March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database studyToby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
British Journal of Haematology|June 22, 2019
Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphomaFaouzi Djebbari, Joseph A Browning, Louise Stanton, et al.
British Journal of Haematology|March 21, 2022
Guideline for the treatment of chronic lymphocytic leukaemiaRenata Walewska, Nilima Parry-Jones, Toby A Eyre, et al.
Blood Advances|April 19, 2024
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S Davids, Jeff P Sharman, Paolo Ghia, et al.
British Journal of Haematology|May 19, 2025
Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology GuidelineSridhar Chaganti, Christopher P Fox, Bernard D Maybury, et al.
Haematologica|September 8, 2018
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A Eyre, Harriet S Walter, Sunil Iyengar, et al.
Haematologica|December 15, 2022
Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinibAlexander P Bye, Neline Kriek, Tanya Sage, et al.
Pageof 17

Showing results (71-80 of 163) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|June 14, 2021
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)Toby A Eyre, Gavin Preston, Huseini Kagdi, et al.
Blood Advances|February 11, 2020
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemiaVictoria M Smith, Oliver Lomas, Donna Constantine, et al.
British Journal of Haematology|January 22, 2024
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology GuidelineChristopher P Fox, Sridhar Chaganti, Graham McIlroy, et al.
Leukemia & Lymphoma|March 29, 2023
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database studyToby A Eyre, Lisa M Hess, Tomoko Sugihara, et al.
British Journal of Haematology|June 22, 2019
Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphomaFaouzi Djebbari, Joseph A Browning, Louise Stanton, et al.
British Journal of Haematology|March 21, 2022
Guideline for the treatment of chronic lymphocytic leukaemiaRenata Walewska, Nilima Parry-Jones, Toby A Eyre, et al.
Blood Advances|April 19, 2024
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S Davids, Jeff P Sharman, Paolo Ghia, et al.
British Journal of Haematology|May 19, 2025
Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology GuidelineSridhar Chaganti, Christopher P Fox, Bernard D Maybury, et al.
Haematologica|September 8, 2018
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A Eyre, Harriet S Walter, Sunil Iyengar, et al.
Haematologica|December 15, 2022
Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinibAlexander P Bye, Neline Kriek, Tanya Sage, et al.
Pageof 17